Please provide your email address to receive an email when new articles are posted on . In the Disrupt BTK pilot study, intravascular lithotripsy successfully treated calcified and stenotic ...
Coronary Artery Disease (CAD) is the most common heart disease and most frequent cause of death in the U.S., with over 20 million adults affected by this condition Abbott (ABT)'s investigational ...
Gift Article 10 Remaining As a subscriber, you have 10 articles to gift each month. Gifting allows recipients to access the article for free. Abbott Laboratories is launching a new clinical trial to ...
MILPITAS, Calif. , Oct. 01, 2025 (GLOBE NEWSWIRE) -- Elixir Medical, a developer of disruptive technologies to treat cardiovascular disease, today announced key milestone and full market release of ...
PARIS--(BUSINESS WIRE)--Elixir Medical, a developer of transformative technologies to treat cardiovascular and peripheral disease, today announced that the PINNACLE I study evaluating the safety and ...
MILPITAS, Calif., April 25, 2025 (GLOBE NEWSWIRE) -- Elixir Medical, a developer of disruptive technologies to treat cardiovascular disease, today announced the first clinical use of its LithiX™ Hertz ...
Avvio Medical, Inc., a clinical-stage medical device company developing next-generation kidney stone treatment technologies, today announced that the U.S. Food and Drug Administration (FDA) has ...
MILAN--(BUSINESS WIRE)--Quanta System SpA (El.En. Group – Mid Cap Star Segment of the Italian Stock Exchange – ELN.MI) announces today a very important milestone in developing a new laser technology, ...
CENTER VALLEY, Pa., April 10, 2018 /PRNewswire/ -- On April 10, 2018, Olympus signed a definitive agreement to acquire lithotripsy system design and production technology from Cybersonics, Inc., based ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results